Mydfrin

Small molecule

MMontefiore Medical Center

Mydfrin is one of 18 small molecule programs targeting Mitral regurgitation. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mitral RegurgitationActive, not recruiting

Mitral RegurgitationPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Mitral Regurgitation

#DrugCompanyPhaseTrials

Atacand

AstraZeneca

Approved

1 2

LCZ696

Novartis

Approved

1 3

Farxiga

AstraZeneca

Phase 3

3 4

Steglatro

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 5

Atacand

AstraZeneca

Approved

1 6

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 7

Aldactone

Pfizer

Preclinical

2 8

Plavix

Sanofi

Preclinical

1 9

Bayer Aspirin

Bayer

Preclinical

1 10

Demadex

SSarfez Pharmaceuticals, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mitral regurgitation1 trial

Use of Phenylephrine for Assessment of Mitral Regurgitation Severity

Recruiting·MMontefiore Medical Center·Phase 1/2·NCT04500899·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mydfrin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mydfrin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mydfrin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Montefiore Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: MMontefiore Medical Center

Mydfrin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mitral regurgitation1 trial

References

Drug Info

Quick Facts

Related News